Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?

Samuel L. Aitken, Farnaz Foolad, Patrick M. McDaneld
Samuel L. Aitken
aDivision of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
bCenter for Antimicrobial Resistance and Microbial Genomics (CARMiG), UT Health McGovern Medical School, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farnaz Foolad
aDivision of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick M. McDaneld
aDivision of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.01160-17
  • Article
  • Info & Metrics
  • PDF
Loading

LETTER

We read the recent paper by Cheng et al. with interest and commend the authors for assessing the clinically important question of whether piperacillin-tazobactam can be used as definitive therapy for bacteremia caused by Enterobacteriaceae harboring inducible AmpC β-lactamases (1). However, we disagree with the main conclusions of the paper, namely, that definitive therapy with piperacillin-tazobactam is no different than definitive therapy with either cefepime or meropenem.

In the propensity score-matched cohort, both 30-day mortality and persistent bacteremia were numerically doubled in patients receiving piperacillin-tazobactam versus those receiving cefepime or meropenem, although the reported odds ratio (OR) for 30-day mortality is 0.5 (Table 3 in reference 1). Similarly, unadjusted 30-day mortality was lower for recipients of piperacillin-tazobactam in the overall cohort, but the reported odds ratio for 30-day mortality is 1.16. Could the control group or mortality have been misclassified in these analyses? Although the lack of statistical significance for the comparison does not change, the qualitative interpretation of the findings is fundamentally reversed.

An additional consideration lies in the use of propensity score-based modeling. Although propensity scores may increase precision and reduce bias when assessing relatively uncommon events, standard multivariable logistic regression models may outperform propensity score-based models when a sufficient number of events are observed (2). In this case, the more limited propensity score-matched cohort included only 82 of the original 165 patients and reduced the observed mortality events from 18 to 9. Under these conditions, the use of propensity score matching may have increased model bias and, through reduction of the number of patients, led to a loss of power and a possible type 2 error. Was a standard multivariable logistic regression model that adjusted for severity of illness considered?

The numerical increase in mortality and persistent bacteremia are consistent with the results of a recent study performed by Harris and colleagues addressing risk factors for recurrence in patients with monomicrobial Enterobacter species bacteremia (3). In this study, the univariate odds of recurrence were nearly doubled for those who received piperacillin-tazobactam or ticarcillin-clavulanate compared to those who received carbapenems (OR, 1.83; 95% confidence interval [CI], 0.64 to 5.21; P = 0.26). Although only 21 patients received definitive therapy with a β-lactam or β-lactamase inhibitor and the finding was not statistically significant, taken together, these two studies lead to significant concerns regarding the use of piperacillin-tazobactam as definitive therapy for bacteremia caused by Enterobacteriaceae with inducible AmpC β-lactamases. Further research is needed to define the role of piperacillin-tazobactam as a treatment for these challenging infections.

FOOTNOTES

  • For the author reply, see https://doi.org/10.1128/AAC.01163-17.

  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Cheng L,
    2. Nelson BC,
    3. Mehta M,
    4. Seval N,
    5. Park S,
    6. Giddins MJ,
    7. Shi Q,
    8. Whittier S,
    9. Gomez-Simmonds A,
    10. Uhlemann AC
    . 2017. Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother61:e00276-17. doi:10.1128/AAC.00276-17.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Cepeda MS,
    2. Boston R,
    3. Farrar JT,
    4. Strom BL
    . 2003. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol158:280–287. doi:10.1093/aje/kwg115.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Harris PNA,
    2. Peri AM,
    3. Pelecanos AM,
    4. Hughes CM,
    5. Paterson DL,
    6. Ferguson JK
    . 2017. Risk factors for relapse or persistence of bacteraemia caused by Enterobacter spp.: a case-control study. Antimicrob Resist Infect Control6:14. doi:10.1186/s13756-017-0177-0.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?
Samuel L. Aitken, Farnaz Foolad, Patrick M. McDaneld
Antimicrobial Agents and Chemotherapy Aug 2017, 61 (9) e01160-17; DOI: 10.1128/AAC.01160-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Should Piperacillin-Tazobactam Be Used as Definitive Therapy against Enterobacteriaceae Harboring Inducible AmpC β-Lactamases?
Samuel L. Aitken, Farnaz Foolad, Patrick M. McDaneld
Antimicrobial Agents and Chemotherapy Aug 2017, 61 (9) e01160-17; DOI: 10.1128/AAC.01160-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • FOOTNOTES
    • REFERENCES
  • Info & Metrics
  • PDF

KEYWORDS

Enterobacteriaceae
piperacillin
cefepime
meropenem
Enterobacter
antimicrobial stewardship
bacteremia

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596